New Jersey · 2026-2027 Regular Session · Bill

A 4550: Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

In committee Last action March 10, 2026: Introduced, Referred to Assembly Financial Institutions and Insurance Committee

Plain-language summary

A 4550 is a bill introduced in the New Jersey House on March 10, 2026. According to its official title, it concerns: Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols. Primary sponsor: Carol Murphy (Democratic). Most recent recorded action (March 10, 2026): Introduced, Referred to Assembly Financial Institutions and Insurance Committee.

Sponsors

Primary sponsor: Carol Murphy (Democratic).